News Releases News Releases HOME HOME

December 24, 2002

Petition for the Approval of RiUP for Women

On December 20, 2002 (Friday), Taisho Pharmaceutical Co., Ltd. (President: Akira Uehara) filed a petition for the approval of a hair growth agent, which it developed to treat female pattern alopecia.

Clinical trials for the "RiUP for Women" were begun in October of 2000 and completed in June of 2002.
The currently popular "RiUP" is limited to use by men. However, many women have expressed interest in using "RiUP" and Taisho has proceeded with development to meet their demands.
In a survey conducted by Taisho regarding the problems women have with their hair, many women responded by citing things such as "no fullness", "no bounce", "loss of hair", "thinness of strands" and "lack of thickness".

The main ingredient, minoxidil, is a hair growth component that was developed by the U.S. Pharmacia-Upjohn company (currently the Pharmacia Corporation). It was submitted for approval to the Food and Drug Administration (FDA) in 1986 and went on sale in 1988 after receiving approval as a drug for medical use. Later, in 1993 it was submitted for approval as a non-prescription (OTC) drug. Approval was granted in 1996 and sales were begun in the same year. When it first hit the market, it enjoyed great popularity as the only hair growth drug recognized as effective by the FDA. Even today, it continues to be sold over the counter while maintaining the lion’s share of the market.
It is sold in the U.S. as "Rogaine" and in the EU and other countries as "Regaine". As of November 2002 it was being sold as an over the counter drug in 41 out of the 94 countries where it is sold

The minoxidil preparation "RiUP" was the first (direct OTC) drug for medical use sold in Japan as a non-prescription pharmaceutical without first being sold by prescription. Sales began in June of 1999 and had reached 20,000,000 units by July of 2002 (a sales period of 3 years and 1 month). In September of 2002, the large 120mL size went on sale. In keeping with Taisho’s policy of being responsive to consumer requirements, Taisho will continue to develop various new pharmaceuticals in the future.